Butterfly Network Appoints Caroll Neubauer to Board

Butterfly Network ( (BFLY) ) has provided an announcement.

Butterfly Network, Inc., a leader in semiconductor-based ultrasound devices and AI-enabled imaging platforms, has built a portfolio spanning point-of-care devices, cloud-based workflow software, AI marketplaces and an Ultrasound-on-Chip licensing arm to embed its technology into broader healthcare and adjacent markets. Its strategy centers on leveraging proprietary hardware and software to expand ultrasound adoption and enable third-party innovation.

On May 4, 2026, Butterfly director Dr. Erica Schwartz notified the board she would resign as a director if and when confirmed by the U.S. Senate as Director of the Centers for Disease Control and Prevention, following her April 16, 2026 nomination, while remaining a nominee for Butterfly’s June 18, 2026 annual meeting. On May 7, 2026, the board appointed longtime medtech executive Caroll H. Neubauer as an independent director effective May 18, 2026, expanding the board to eight members, adding him to the compensation and technology committees, and granting him a standard nonemployee director compensation package including three-year vesting RSUs.

Neubauer, the former chairman and CEO of B. Braun of America and a three-decade veteran of the B. Braun Group’s global management board, brings deep experience in scaling a major medical device maker, navigating complex regulation and building global partnerships, credentials Butterfly sees as directly relevant to its evolution into a multi-faceted platform. His appointment signals Butterfly’s push to strengthen governance and industry ties as it pursues profitability and multiple growth initiatives, a move likely to be watched by investors and partners seeking evidence of disciplined expansion and strategic execution.

The most recent analyst rating on (BFLY) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Butterfly Network stock, see the BFLY Stock Forecast page.

Spark’s Take on BFLY Stock

According to Spark, TipRanks’ AI Analyst, BFLY is a Neutral.

The score is held back primarily by weak profitability and continued cash burn despite improving trends and a low-debt balance sheet. Technicals are moderately supportive, while the earnings call added positives around growth, margin expansion, and reiterated guidance. Valuation remains a constraint because the company is still loss-making and offers no dividend yield.

To see Spark’s full report on BFLY stock, click here.

More about Butterfly Network

Butterfly Network, Inc. is a medtech company and pioneer in semiconductor-based ultrasound devices, programmable cloud software and AI, focused on making affordable, accessible ultrasound widely available. It first proved its technology in point-of-care ultrasound with its Butterfly iQ3 single-probe, whole-body portable device, and now augments its hardware with enterprise workflow software, AI tools and its Butterfly Embedded Ultrasound-on-Chip licensing business.

Average Trading Volume: 5,909,972

Technical Sentiment Signal: Buy

Current Market Cap: $1.11B

For a thorough assessment of BFLY stock, go to TipRanks’ Stock Analysis page.